8-K: Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors; Carl Gordon Resigns

Terns Pharmaceuticals appoints Robert Azelby to its Board of Directors, effective immediately, while Carl Gordon steps down after seven years of service.

Summary

• Terns Pharmaceuticals announced the appointment of Robert Azelby to its Board of Directors, effective February 20, 2025.
• Carl Gordon resigned from the Board on the same day after serving for more than seven years.
• Robert Azelby was appointed as a Class I director until the 2025 annual meeting of stockholders.
• He will also serve as a member of the Compensation Committee.
• Upon his election, Mr. Azelby was granted an option to purchase 90,000 shares of common stock, vesting over three years.
• The company issued a press release announcing these changes.
• Mr. Azelby previously served as CEO of Eliem Therapeutics and Alder BioPharmaceuticals, and held positions at Juno Therapeutics and Amgen Inc.
• Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule product candidates for oncology and obesity.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the appointment of an experienced executive to the board and the company's progress in its clinical programs. However, the resignation of a long-standing board member introduces a slight element of uncertainty.

Positives

• Robert Azelby's extensive experience as a biotechnology executive and board director is expected to benefit Terns Pharmaceuticals.
• Azelby's background in developing and commercializing cancer treatments is seen as valuable as Terns prepares TERN-701 for late-stage studies in chronic myeloid leukemia.
• Terns is advancing its lead oncology and obesity programs towards important clinical readouts later this year.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties, as detailed in the company's SEC filings.
• Actual results could vary materially from these forward-looking statements.

Future Outlook

Terns is advancing its lead oncology and obesity programs towards important clinical readouts later this year and is well-positioned for continued success as it advances its class leading programs forward.

Management Comments

• 'I am thrilled to welcome Bob to the Terns Board as he brings extensive strategic and operational leadership across multiple therapeutic indications and stages of development,' said Amy Burroughs, chief executive officer of Terns.
• 'I am pleased to be joining Terns as we advance our lead oncology and obesity programs towards important clinical readouts later this year,' said Mr. Azelby.
• 'I remain confident that Terns is well-positioned for continued success as it advances its class leading programs forward,' added Dr. Gordon.

Industry Context

The appointment of a seasoned biotechnology executive like Robert Azelby reflects a common strategy in the biopharmaceutical industry to bring in experienced leaders to guide companies through critical stages of development and commercialization, particularly as they advance clinical programs and prepare for potential market entry. Azelby's previous roles at companies like Eliem Therapeutics, Alder BioPharmaceuticals, Juno Therapeutics, and Amgen highlight his extensive experience across various therapeutic areas and stages of development.

Comparison to Industry Standards

• Robert Azelby's career trajectory is comparable to other seasoned biotechnology executives who have held leadership positions at multiple companies, such as Amgen, Juno Therapeutics and Eliem Therapeutics.
• His experience in oncology, particularly his time at Juno Therapeutics and Amgen, aligns with the industry trend of focusing on innovative cancer treatments.
• His board memberships at ADC Therapeutics and Autolus Therapeutics, companies focused on antibody-drug conjugates and cell therapies respectively, indicate his involvement in cutting-edge areas of cancer research.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of Robert Azelby positively, given his extensive experience and potential to contribute to the company's strategic direction.
• The change in board membership could impact the company's decision-making processes and strategic priorities.
• Employees may be affected by any shifts in company strategy or priorities resulting from the new board member's influence.

Next Steps

• Mr. Azelby will serve on the Board and Compensation Committee.
• Mr. Azelby and the Company will enter into the Company's standard form of indemnification agreement.
• Terns will continue to advance its oncology and obesity programs towards clinical readouts later this year.

Key Dates

Keywords

Terns Pharmaceuticals, Robert Azelby, Board of Directors, Carl Gordon, biopharmaceutical, oncology, obesity, TERN-701, clinical trials, small-molecule